Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Merck Animal Health has launched its Innovax ND-ILT vaccine for poultry in the US.
US biotechnology firm Mazen Animal Health is ready to scale up its R&D for low-cost oral recombinant vaccines.
AgResults is going to follow up the success of its ongoing brucellosis vaccine development competition with a project focused on developing a vaccine for foot-and-mouth disease (FMD).
Authorities in Argentina have approved an anti-viral foot-and-mouth disease (FMD) vaccine developed by local company CDV Laboratory
Spanish biotechnology company VLPbio has secured a license option deal with an unnamed partner for its vaccine candidate against porcine reproductive and respiratory syndrome (PRRS).
Swiss start-up Malcisbo is looking for investment to further develop its glyco-conjugate poultry and swine vaccines.
Boehringer Ingelheim's ReproCyc ParvoFLEX vaccine has moved one step closer to European approval after gaining a positive opinion ruling from authorities.
Spanish biotechnology firm Algenex has progressed to its next stage of development after securing approximately €4 million ($4.5 million) in investment.
Laboratorios Hipra Canada has launched Vepured, which is a vaccine to tackle edema disease in its clinical and subclinical form in pigs.
Ceva Santé Animale is bringing Ultifend IBD ND to the US poultry market in the coming weeks.
Spanish firm Laboratorios Syva has secured European approval for Syvazul BTV – an inactivated multi-strain vaccine against bluetongue disease caused by serotypes 1, 4 and 8.
Merck Animal Health is pouring investment into its manufacturing and warehousing site in Millsboro, Delaware.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.